Literature DB >> 8619575

Decreased activity of erythromycin against Streptococcus pyogenes in Taiwan.

P R Hsueh1, H M Chen, A H Huang, J J Wu.   

Abstract

A total of 78 clinical isolates of Streptococcus pyogenes were collected from January 1992 through December 1993 from patients in southern Taiwan. The in vitro activities of 10 antimicrobial agents were determined by the agar dilution method. Penicillin, cephalothin, cefotaxime, vancomycin, and ofloxacin were shown to be active against S. pyogenes isolates, with MICs at which 90% of isolates are inhibited (MIC90s) being < or = 0.03, < or = 0.13, < or = 0.13, < or = 0.13, and < or = 0.25 microgram/ml, respectively. Erythromycin and azithromycin both had poor activities (MIC50s, 16 and >128 micrograms/ml, respectively; MIC90s, >128 and >128 micrograms/ml, respectively). The activities of tetracycline, clindamycin, and chloramphenicol against a significant number of these isolates were also limited. As the MICs of clindamycin and chloramphenicol for the isolates increased, the MICs of the two macrolides also increased. Clindamycin, chloramphenicol, and the two macrolides were less potent against isolates recovered form throat swab samples than against those from blood or other sources. Isolates of the T12 and T1 serotypes accounted for 53.8% of all isolates. The majority (87.5%) of the isolates recovered from throat swab samples were of the T12 serotype, whereas 19.2% of the isolates recovered from blood were of the T12 serotype. In contrast, 66.7% of the isolates of the T1 serotype were derived from blood but none were derived from throat swab samples. Of the 33 T12 serotype isolates, erythromycin MICs for 78.8% of the isolates were >128 micrograms/ml. Because of the poor activities of erythromycin and azithromycin against S. pyogenes isolates from patients in southern Taiwan, these drugs should no longer be considered the drugs of choice for the management of group A streptococcal infections among patients who live in this area.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8619575      PMCID: PMC162922          DOI: 10.1128/AAC.39.10.2239

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Global surveillance of antibiotic resistance.

Authors:  T F O'Brien
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

2.  Resistance to erythromycin in group A streptococci.

Authors:  H Seppälä; A Nissinen; H Järvinen; S Huovinen; T Henriksson; E Herva; S E Holm; M Jahkola; M L Katila; T Klaukka
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

3.  Erythromycin-resistant Streptococcus pyogenes.

Authors:  G Phillips; D Parratt; G V Orange; I Harper; H McEwan; N Young
Journal:  J Antimicrob Chemother       Date:  1990-04       Impact factor: 5.790

4.  Outbreaks of infections with erythromycin-resistant group A streptococci in child day care centres.

Authors:  L Holmström; B Nyman; M Rosengren; S Wallander; T Ripa
Journal:  Scand J Infect Dis       Date:  1990

5.  Infections with beta-Hemolytic Streptococcus resistant to lincomycin and erythromycin and observations on zonal-pattern resistance to lincomycin.

Authors:  J M Dixon; A E Lipinski
Journal:  J Infect Dis       Date:  1974-10       Impact factor: 5.226

6.  Decline of erythromycin resistance of group A beta-hemolytic streptococci in Japan. Comparison with worldwide reports.

Authors:  J W Bass; M E Weisse; M R Plymyer; S Murphy; B J Eberly
Journal:  Arch Pediatr Adolesc Med       Date:  1994-01

7.  Stepwise acquisition of multiple drug resistance by beta-hemolytic streptococci and difference in resistance pattern by type.

Authors:  Y Miyamoto; K Takizawa; A Matsushima; Y Asai; S Nakatsuka
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

8.  Current antibiotic susceptibility of group A beta-hemolytic streptococci.

Authors:  P Bourbeau; J M Campos
Journal:  J Infect Dis       Date:  1982-06       Impact factor: 5.226

9.  Preparation of Streptococcus pyogenes suspensions for typing by the agglutination method.

Authors:  A Efstratiou
Journal:  Med Lab Sci       Date:  1980-10

10.  Sensitivity of group A streptococci to antibiotics. Prevalence of resistance to erythromycin in Japan.

Authors:  S Maruyama; H Yoshioka; K Fujita; M Takimoto; Y Satake
Journal:  Am J Dis Child       Date:  1979-11
View more
  17 in total

1.  Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada.

Authors:  J C De Azavedo; R H Yeung; D J Bast; C L Duncan; S B Borgia; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan.

Authors:  P R Hsueh; L J Teng; L N Lee; S W Ho; P C Yang; K T Luh
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

3.  Emergence of erythromycin-resistant, clindamycin-susceptible Streptococcus pyogenes isolates in Madrid, Spain.

Authors:  I Garcia-Bermejo; J Cacho; B Orden; J I Alós; J L Gómez-Garcés
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

4.  Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods.

Authors:  E L Fasola; S Bajaksouzian; P C Appelbaum; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Prevalence of polyclonal mefA-containing isolates among erythromycin-resistant group A streptococci in Southern Taiwan.

Authors:  J J Yan; H M Wu; A H Huang; H M Fu; C T Lee; J J Wu
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

6.  Antimicrobial susceptibility of flavobacteria as determined by agar dilution and disk diffusion methods.

Authors:  J C Chang; P R Hsueh; J J Wu; S W Ho; W C Hsieh; K T Luh
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

7.  Emergence of Streptococcus pyogenes strains resistant to erythromycin in Gipuzkoa, Spain.

Authors:  E Perez-Trallero; M Urbieta; M Montes; I Ayestaran; J M Marimon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-01       Impact factor: 3.267

8.  Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California.

Authors:  M K York; L Gibbs; F Perdreau-Remington; G F Brooks
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

9.  Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain.

Authors:  C García-Rey; L Aguilar; F Baquero; J Casal; J E Martín
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

10.  Epidemiology and molecular characterization of macrolide-resistant Streptococcus pyogenes in Taiwan.

Authors:  Chia-Ying Huang; Jui-Fen Lai; I-Wen Huang; Pei-Chen Chen; Hui-Ying Wang; Yih-Ru Shiau; Ya-Wen Cheng; Li-Yun Hsieh; Shan-Chwen Chang; Tsai-Ling Yang Lauderdale
Journal:  J Clin Microbiol       Date:  2013-12-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.